We FINALLY Understand the Power of Psychedelics (...mostly)

Summary

The video traces the history of psychedelic research, from Albert Hofmann’s discovery of LSD to modern studies of how psychedelic compounds may affect brain activity and plasticity. It presents these drugs as promising research tools and possible treatments, while emphasizing that important questions about their effects and how to test them remain unresolved.

History and early experiments

• In 1943, Swiss chemist Albert Hofmann accidentally absorbed LSD while working with compounds derived from rye fungus. He described vivid visual effects, altered time and self-perception, and intense emotions.
• Sandoz Laboratories later distributed LSD, known medically as Delysid, to researchers and clinicians.
• In Saskatchewan, psychiatrists Humphry Osmond and Abram Hoffer conducted early LSD studies. The video notes that their methods would not meet many current scientific standards, though participants’ reports showed recurring patterns such as vivid colors and emotional intensity.
• Psychiatrist Oscar Janiger studied artists drawing a model during LSD sessions. Their drawings often changed as the session progressed, and the video suggests that LSD altered artists’ working methods, though it did not necessarily improve their art.
• Osmond and Hoffer also explored LSD-assisted treatment for alcoholism. They reported that some patients experienced intense self-reflection and stopped relapsing. The video cites their treatment of more than 700 patients by 1957 and an estimated 50% who stopped relapsing, while acknowledging that the mechanism was not understood at the time.

CIA experiments and the serotonin connection

• During the Cold War, the CIA funded LSD research through MK Ultra, including the unethical “Midnight Climax” operation, in which people were secretly given LSD and observed. The agency concluded that the drug was too unpredictable to serve as a reliable mind-control tool.
• In the late 1950s, researchers D. W. Woolley and E. Shaw noticed similarities between LSD and serotonin, a brain chemical involved in mood, perception, and sleep. They proposed that LSD might affect the brain by acting on serotonin-related sites.
• Hofmann later isolated psilocybin and psilocin from Mexican hallucinogenic mushrooms. Like LSD and serotonin, these compounds have an indole-containing chemical structure.
• The video explains that serotonin is released between neurons and binds to receptors. A transporter called SERT then reabsorbs it. SSRIs block SERT, allowing serotonin to remain in the synapse longer.
• Psychedelics act especially on the serotonin receptor 5-HT2A. The video says LSD can remain bound to this receptor much longer than serotonin, and that this activity affects neurons connecting distant cortical regions.

Brain activity and plasticity

• The video describes 2014 Imperial College London fMRI research in which psychedelic use was associated with increased communication between brain regions. It reports connectivity increases of up to 300% in some areas, alongside a 20–30% decrease in the internal coherence of the default mode network, associated with self-reflection and habitual thought.
• These shifts may help explain experiences such as sensory crossover—for example, hearing colors—and changes in self-perception.
• The video also links psychedelic-induced activity to brain-derived neurotrophic factor (BDNF), which may support the growth of dendritic spines and new neural connections. It suggests that temporary changes in brain activity could create opportunities for longer-lasting changes in behavior.
• It contrasts this with trauma and prolonged stress, which can reinforce threat-related patterns and reduce neural flexibility.

Clinical research and treatment structure

• Psilocybin acts on the same 5-HT2A receptor as LSD, but the video describes its effects as shorter—typically four to six hours—and its dosing as easier to measure.
• Research groups at Johns Hopkins, NYU, and Imperial College London have found that the setting and support surrounding a psilocybin session can affect outcomes. The video describes a “therapeutic container” with three parts:
  • Preparation: Patients meet with a trained guide to discuss expectations, fears, and goals.
  • Supported session: A therapist remains present; eye shades and selected music are commonly used to limit outside stimulation and encourage inward focus.
  • Integration: Follow-up sessions help patients interpret the experience and reinforce any changes.
• A phase 2a randomized controlled trial of intravenous DMT, published in Nature Medicine in 2025, is described as involving people with moderate to severe major depressive disorder. The video reports a 10.75-point reduction in depression symptoms compared with placebo at one week, a 7.35-point reduction at two weeks, and measurable benefits in some participants up to six months. These are reported trial results, not proof that DMT is an established treatment.
• The FDA rejected MAPS’ application for MDMA-assisted therapy for PTSD in August 2024. MDMA is not described as a classic psychedelic, and the video says the FDA raised concerns about trial methodology. A key challenge is that the noticeable effects of psychoactive drugs make it difficult to keep patients and clinicians unaware of whether the drug or placebo was given, complicating efforts to control for expectations.

The possibility of “silent” neuroplasticity

• The video describes research suggesting that the neural plasticity effects of psychedelics may be separable from their hallucinogenic effects. It proposes that molecules able to enter neurons may activate intracellular 5-HT2A receptors involved in growth signals.
• A candidate compound, tabernanthalog (TBG), is presented as a partial 5-HT2A agonist that may promote dendritic-spine growth without triggering the same level of hallucinogenic activity. In animal models, it reportedly does not cause the “head twitch” response often used as a proxy for hallucination in rodents.
• TBG has not yet entered human trials. If this line of research proves successful, it could potentially offer neuroplastic effects without a prolonged psychedelic experience; the video presents this as a possibility, not a demonstrated clinical outcome.
• The video concludes that psychedelic effects may be more than the subjective “trip”: temporary changes to brain networks could provide an opportunity for new patterns of thought and behavior to form.

Researchers and sources featured

Named researchers

• Albert Hofmann
• Humphry Osmond
• Abram Hoffer
• Oscar Janiger
• D. W. Woolley
• E. Shaw

Research institutions, organizations, and publications mentioned

• Sandoz Laboratories
• Rockefeller Institute
• Imperial College London
• Johns Hopkins University
• New York University (NYU)
• Multidisciplinary Association for Psychedelic Studies (MAPS)
• Nature Medicine (the 2025 DMT trial)
• The U.S. Food and Drug Administration (FDA)